Developer docs
API playgroundTry for free, no card

Search company profiles

Takeda Canada

Full company profile

uuid0007zbx

Namestring
Takeda Canada
Legal namestring
Takeda Pharmaceutical Company Limited
Websiteurl
takeda.com
Company typeenum
Public
Founded yearint
1781
Descriptiontext

Takeda Canada Inc. is a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, a Japanese-headquartered multinational pharmaceutical company founded in 1781 and publicly traded on the Tokyo Stock Exchange (TSE:4502) and NYSE (NYSE:TAK). Operating from Toronto with 1001-5000 employees in Canada, the subsidiary commercializes Takeda's specialty pharmaceutical portfolio across six core therapeutic areas: gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines. Key Canadian-commercialized products include FRUZAQLA (fruquintinib), a VEGF receptor inhibitor for metastatic colorectal cancer that received Health Canada market authorization in September 2024 and is now reimbursed in at least seven Canadian provinces including Ontario and British Columbia.

The company's underlying technology is rooted in proprietary small-molecule and biologic drug development, with differentiated pipeline assets including zasocitinib (TAK-279), a next-generation oral TYK2 inhibitor with >1-million-fold selectivity versus other JAK enzymes, and oveporexton (TAK-861), an orexin receptor 2-selective agonist for narcolepsy type 1 that received FDA Priority Review with a Q3 2026 PDUFA goal date. Takeda's dengue vaccine, with seven years of protection demonstrated in Phase 3 trials across 20,000+ participants in Latin America and Asia, is projected to reach approximately $1.6 billion in annual sales by 2030. The parent employs staff across approximately 80 countries and operates manufacturing facilities including the Singen site in Germany.

Takeda's revenue model is based on one-time prescription pharmaceutical product sales distributed through direct sales to healthcare institutions, pharmacy distribution networks, and government reimbursement programs including provincial exceptional access programs in Canada. Go-to-market is sales-led, executed through pharmaceutical sales representatives promoting approved drugs to healthcare providers and institutional buyers. The company is led by newly appointed President and CEO Julie Kim (effective June 2026), succeeding Christophe Weber after 12 years. The business is highly dependent on regulatory approvals and payer reimbursement decisions; Canadian revenue concentration in provincial government payers creates moderate concentration risk offset by prescriber-level distribution across hospitals, clinics, and pharmacies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersToronto, Canada
HQ citystring
Toronto
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty pharmaceuticals, oncology therapeutics, rare disease treatments, plasma-derived therapies, vaccines and biologics
Industry2 codes
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAEAK
Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
NAICS code3 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Specialty Pharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Takeda generates revenue primarily through the sale of prescription pharmaceutical products across its core therapeutic areas including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Products are sold through various channels including direct sales to healthcare providers and institutional buyers.

takeda.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1FRUZAQLA (fruquintinib capsules)
Description

A treatment for metastatic colorectal cancer (mCRC) that received Health Canada market authorization in September 2024 and is reimbursed in multiple Canadian provinces.

newswire.ca
Core offering1 text field

Takeda Canada is the Canadian subsidiary of Takeda Pharmaceutical Company Limited, focused on developing, manufacturing, and commercializing specialty prescription medicines for gastrointestinal and inflammatory diseases, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines. The company markets approved products such as FRUZAQLA (fruquintinib) for metastatic colorectal cancer and is advancing late-stage pipeline assets including zasocitinib (TAK-279) for plaque psoriasis and oveporexton (TAK-861) for narcolepsy type 1.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Approximately 70% of patients achieved clear or almost clear skin (sPGA 0/1) at week 16 with zasocitinib in Phase 3 plaque psoriasis studies
+5 more records
Product and service1 record
1FRUZAQLA (fruquintinib capsules)
CategoryOncology Therapeutics
Description

Oral VEGF receptor inhibitor (fruquintinib capsules) for the treatment of adult patients with metastatic colorectal cancer who have exhausted standard therapy options; reimbursed in multiple Canadian provinces through government exceptional access programs.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-04-05
Description

Takeda previously collaborated with Denali Therapeutics to co-develop and co-commercialize DNL593, an investigational progranulin replacement therapy for frontotemporal dementia-granulin (FTD-GRN). Takeda terminated the collaboration agreement driven by strategic considerations unrelated to safety or efficacy. Denali will regain full control of DNL593 and its intellectual property portfolio.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Global R&D-driven pharmaceutical company with comparable scale, multi-therapeutic-area pipeline (oncology, immunology, vaccines, neuroscience), and similar global commercial footprint across ~80+ countries; competes directly with Takeda in oncology, vaccines, and rare diseases.

TypeDirect peer
Description

Major oncology and immunology-focused pharmaceutical company with comparable R&D scale and therapeutic-area overlap; competes with Takeda in colorectal cancer (FRUZAQLA competes with bevacizumab-based regimens) and immunology.

TypeDirect peer
Description

Leader in immunology (Humira/Skyrizi/Rinvoq) directly competing with Takeda's TYK2 franchise; AbbVie's neuroscience and oncology pipelines overlap with Takeda's, and both pursue branded-innovator commercial strategies post-major acquisitions.

TypeDirect peer
Description

Oncology and rare-disease focused pharmaceutical company with comparable global commercial reach; competes with Takeda in colorectal cancer and increasingly in immunology, with similar innovator-pharma business model.

TypeDirect peer
Description

Swiss multinational with overlapping franchises in oncology, immunology, and neuroscience; competes with Takeda in specialty therapeutics and shares the innovator-branded pharmaceutical business model with similar pipeline depth and global commercialization capabilities.

TypeDirect peer
Description

Key oncology competitor with overlapping solid-tumor pipeline and global launch capabilities; Merck's vaccine franchise (including pneumococcal and pipeline assets) competes with Takeda's dengue vaccine, while oncology overlap extends to colorectal cancer.

TypeDirect peer
Description

European multinational with strong rare-disease and immunology franchises overlapping Takeda's post-Shire portfolio; comparable scale, multi-area pipeline, and global commercialization including in Canadian provincial reimbursement markets.

TypeDirect peer
Description

Global pharmaceutical company with strong vaccine franchise directly overlapping Takeda's dengue vaccine ambitions; also competes in oncology and immunology with similar innovator-pharma commercial model and global distribution.

9Bristol-Myers Squibb
TypeDirect peer
Description

Direct oncology and immunology competitor with overlapping pipelines in solid tumors and inflammatory diseases; both companies emphasize branded innovator pharmaceuticals and operate similar global commercial models.

TypeBroad incumbent
Description

Diversified pharmaceutical incumbent with oncology, immunology, and neuroscience franchises overlapping Takeda's core therapeutic areas; broader portfolio (medical devices, consumer) but operates as a comparable large-cap branded pharmaceutical peer in similar global markets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Takeda Canada

Specialty Pharmaceuticalstakeda.com

What Takeda Canada does

Takeda Canada Inc. is a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, a Japanese-headquartered multinational pharmaceutical company founded in 1781 and publicly traded on the Tokyo Stock Exchange (TSE:4502) and NYSE (NYSE:TAK). Operating from Toronto with 1001-5000 employees in Canada, the subsidiary commercializes Takeda's specialty pharmaceutical portfolio across six core therapeutic areas: gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines. Key Canadian-commercialized products include FRUZAQLA (fruquintinib), a VEGF receptor inhibitor for metastatic colorectal cancer that received Health Canada market authorization in September 2024 and is now reimbursed in at least seven Canadian provinces including Ontario and British Columbia.

The company's underlying technology is rooted in proprietary small-molecule and biologic drug development, with differentiated pipeline assets including zasocitinib (TAK-279), a next-generation oral TYK2 inhibitor with >1-million-fold selectivity versus other JAK enzymes, and oveporexton (TAK-861), an orexin receptor 2-selective agonist for narcolepsy type 1 that received FDA Priority Review with a Q3 2026 PDUFA goal date. Takeda's dengue vaccine, with seven years of protection demonstrated in Phase 3 trials across 20,000+ participants in Latin America and Asia, is projected to reach approximately $1.6 billion in annual sales by 2030. The parent employs staff across approximately 80 countries and operates manufacturing facilities including the Singen site in Germany.

Takeda's revenue model is based on one-time prescription pharmaceutical product sales distributed through direct sales to healthcare institutions, pharmacy distribution networks, and government reimbursement programs including provincial exceptional access programs in Canada. Go-to-market is sales-led, executed through pharmaceutical sales representatives promoting approved drugs to healthcare providers and institutional buyers. The company is led by newly appointed President and CEO Julie Kim (effective June 2026), succeeding Christophe Weber after 12 years. The business is highly dependent on regulatory approvals and payer reimbursement decisions; Canadian revenue concentration in provincial government payers creates moderate concentration risk offset by prescriber-level distribution across hospitals, clinics, and pharmacies.

Takeda Canada firmographics

Firmographics
Name
Takeda Canada
Legal name
Takeda Pharmaceutical Company Limited
Website
https://takeda.com
Company type
Public
Founded year
1781
Operating status
Operating
Headcount range
101–250 employees
Ownership category
akta.pro rank

Takeda Canada industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAEAK
Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

Keywords

  • Specialty pharmaceuticals
  • Oncology therapeutics
  • Rare disease treatments
  • Plasma-derived therapies
  • Vaccines and biologics

Where Takeda Canada is headquartered

Location

Headquarters

HQ city
Toronto
HQ country
Canada
HQ region
North America

Offices2 records

Markets served

Takeda Canada business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Pharmaceutical Product Sales: Takeda generates revenue primarily through the sale of prescription pharmaceutical products across its core therapeutic areas including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Products are sold through various channels including direct sales to healthcare providers and institutional buyers.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Takeda Canada product offering

Product offering

Core offering

Takeda Canada is the Canadian subsidiary of Takeda Pharmaceutical Company Limited, focused on developing, manufacturing, and commercializing specialty prescription medicines for gastrointestinal and inflammatory diseases, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines. The company markets approved products such as FRUZAQLA (fruquintinib) for metastatic colorectal cancer and is advancing late-stage pipeline assets including zasocitinib (TAK-279) for plaque psoriasis and oveporexton (TAK-861) for narcolepsy type 1.

Differentiator

Problem solved

Functional benefit

Brands

  • FRUZAQLA (fruquintinib capsules): A treatment for metastatic colorectal cancer (mCRC) that received Health Canada market authorization in September 2024 and is reimbursed in multiple Canadian provinces.

Products and services

  • FRUZAQLA (fruquintinib capsules) Oral VEGF receptor inhibitor (fruquintinib capsules) for the treatment of adult patients with metastatic colorectal cancer who have exhausted standard therapy options; reimbursed in multiple Canadian provinces through government exceptional access programs.

Quantifiable outcome

  • Approximately 70% of patients achieved clear or almost clear skin (sPGA 0/1) at week 16 with zasocitinib in Phase 3 plaque psoriasis studies
  • +5 more outcomes

Companies that use Takeda Canada

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Takeda Canada technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Takeda Canada partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Denali TherapeuticsminorStrategic or Co-development Partner · 5 April 2026Takeda previously collaborated with Denali Therapeutics to co-develop and co-commercialize DNL593, an investigational progranulin replacement therapy for frontotemporal dementia-granulin (FTD-GRN). Takeda terminated the collaboration agreement driven by strategic considerations unrelated to safety or efficacy. Denali will regain full control of DNL593 and its intellectual property portfolio.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Takeda Canada competitors and assessment

Company assessment

Direct peers

  • Pfizer: Global R&D-driven pharmaceutical company with comparable scale, multi-therapeutic-area pipeline (oncology, immunology, vaccines, neuroscience), and similar global commercial footprint across ~80+ countries; competes directly with Takeda in oncology, vaccines, and rare diseases.
  • Roche: Major oncology and immunology-focused pharmaceutical company with comparable R&D scale and therapeutic-area overlap; competes with Takeda in colorectal cancer (FRUZAQLA competes with bevacizumab-based regimens) and immunology.
  • AbbVie: Leader in immunology (Humira/Skyrizi/Rinvoq) directly competing with Takeda's TYK2 franchise; AbbVie's neuroscience and oncology pipelines overlap with Takeda's, and both pursue branded-innovator commercial strategies post-major acquisitions.
  • AstraZeneca: Oncology and rare-disease focused pharmaceutical company with comparable global commercial reach; competes with Takeda in colorectal cancer and increasingly in immunology, with similar innovator-pharma business model.
  • Novartis: Swiss multinational with overlapping franchises in oncology, immunology, and neuroscience; competes with Takeda in specialty therapeutics and shares the innovator-branded pharmaceutical business model with similar pipeline depth and global commercialization capabilities.
  • Merck & Co. Key oncology competitor with overlapping solid-tumor pipeline and global launch capabilities; Merck's vaccine franchise (including pneumococcal and pipeline assets) competes with Takeda's dengue vaccine, while oncology overlap extends to colorectal cancer.
  • Sanofi: European multinational with strong rare-disease and immunology franchises overlapping Takeda's post-Shire portfolio; comparable scale, multi-area pipeline, and global commercialization including in Canadian provincial reimbursement markets.
  • GSK: Global pharmaceutical company with strong vaccine franchise directly overlapping Takeda's dengue vaccine ambitions; also competes in oncology and immunology with similar innovator-pharma commercial model and global distribution.
  • Bristol-Myers Squibb: Direct oncology and immunology competitor with overlapping pipelines in solid tumors and inflammatory diseases; both companies emphasize branded innovator pharmaceuticals and operate similar global commercial models.

Broad incumbents

  • Johnson & Johnson Innovative Medicine: Diversified pharmaceutical incumbent with oncology, immunology, and neuroscience franchises overlapping Takeda's core therapeutic areas; broader portfolio (medical devices, consumer) but operates as a comparable large-cap branded pharmaceutical peer in similar global markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Takeda Canada social profiles

Digital presence

Takeda Canada financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Takeda Canada leadership team

Management profile

Number of profiles

Profiles1 record

Takeda Canada subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Takeda Canada funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Takeda Canada M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Takeda Canada

What does Takeda Canada do?

Takeda Canada is the Canadian subsidiary of Takeda Pharmaceutical Company Limited, focused on developing, manufacturing, and commercializing specialty prescription medicines for gastrointestinal and inflammatory diseases, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines. The company markets approved products such as FRUZAQLA (fruquintinib) for metastatic colorectal cancer and is advancing late-stage pipeline assets including zasocitinib (TAK-279) for plaque psoriasis and oveporexton (TAK-861) for narcolepsy type 1.

Is Takeda Canada a public or private company?

Takeda Canada is a public company. It is classified as public and is currently operating.

When was Takeda Canada founded?

Takeda Canada was founded in 1781. It employs 101 to 250 people.

Where is Takeda Canada based?

Takeda Canada is headquartered in Toronto, Canada, in the North America region.

How does Takeda Canada make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Takeda Canada's main competitors?

Direct peers on record are Pfizer, Roche, AbbVie, AstraZeneca, Novartis, Merck & Co., Sanofi, GSK and Bristol-Myers Squibb. Johnson & Johnson Innovative Medicine is listed as a broad incumbent.

Does Takeda Canada have an API?

No public API is recorded for Takeda Canada.

What industry is Takeda Canada in?

Takeda Canada's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLAAAEAK, Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release). Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Silicon RepublicPharmaceutical Takeda to cut 4,500 from global workforceTakeda announced plans to cut 4,500 jobs from its global workforce, with cuts starting in early July and potentially extending to December 2027. The company will consolidate departments, cut management layers, and automate operations to fund drug launches, while hiring plans remain unaffected. Ireland, where Takeda employs over 1,000, may be impacted, but no specific details were disclosed.The Pharma LetterTakeda entering a new era and transforming for growth accelerationTakeda reported FY2025 revenue of 4,505.7 billion yen ($28.55 billion), down 1.7% year-over-year, driven by Vyvanse exclusivity loss. Core revenue fell 2.6% at constant exchange rates, but the company cited strong OPEX savings and growth from new products.AETOSWireTakeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY202...Takeda reported FY2025 revenue down 1.7% year-over-year, with core revenue down 2.6% at constant exchange rates, but reported operating profit up 19.3% and reported EPS up 78.1%. The company issued FY2026 guidance of 4,640 billion yen revenue and 104 yen EPS, with three major launches planned in the next 12 months.Business Wire BlogTakeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)Takeda announced that its Phase 2/3 trial of TAK-881 in primary immunodeficiency disease met its primary endpoint, showing pharmacokinetic comparability to HYQVIA. The study also demonstrated comparable safety, efficacy, and tolerability, with TAK-881 potentially reducing infusion volume and duration. Takeda expects to submit regulatory applications in fiscal year 2026.The Canadian Press NewsCUPE congratulates Avi Lewis on becoming new leader of Canada's NDPCUPE congratulated Avi Lewis on his election as federal NDP leader at the party's convention in Winnipeg. The union, representing 800,000 workers, said it is ready to work with the NDP to strengthen public services and fight corporate greed. CUPE also thanked interim leader Don Davies for his support.BioSpaceAlan Walshe Appointed General Manager of Takeda CanadaTakeda Canada appointed Alan Walshe as General Manager, bringing 17 years of experience with Takeda and its predecessors. He previously served as Global Head of Commercial Strategy for Plasma-Derived Therapies. He aims to expand access to innovative therapies and strengthen partnerships in Canada.NewswireFRUZAQLA(TM) (fruquintinib capsules) now reimbursed in Ontario to treat metastatic colorectal cancer (mCRC)Takeda Canada announced that FRUZAQLA (fruquintinib capsules) has been added to Ontario's Exceptional Access Program drug reimbursement list for adult patients with metastatic colorectal cancer (mCRC) who have exhausted standard therapy options. Ontario is the seventh Canadian province to reimburse the drug, which received Health Canada market authorization in September 2024 and was recommended for reimbursement by Canada's Drug Agency and INESSS. The treatment provides a new option for mCRC patients, with clinical trial data showing it extended overall survival in refractory metastatic colorectal cancer patients.BioSpaceBritish Columbia reimburses FRUZAQLATM (fruquintinib capsules) for the treatment of metastatic colorectal cancer (mCRC)Takeda Canada Inc. announced on December 16, 2025, that FRUZAQLATM (fruquintinib capsules) will now be reimbursed by BC Cancer for adult patients with metastatic colorectal cancer who have exhausted or are not candidates for standard therapies. The drug, a selective oral VEGFR inhibitor, received Health Canada authorization in September 2024 and a positive reimbursement recommendation from Canada's Drug Agency and INESSS, with over 3,600 people in British Columbia diagnosed with colorectal cancer annually. Takeda stated it remains committed to working with provincial partners to expand patient access across Canada.NewswireTAKEDA CANADA AWARDS $1 MILLION TO SUPPORT THE CANADIAN IBD RESEARCH CONSORTIUMTakeda Canada awarded a $1 million PIONEER Grant to the Canadian Inflammatory Bowel Disease Research Consortium (CIRC) to support clinical research for inflammatory bowel disease. The funding aims to facilitate multi-centre studies and improve diversity, equity, and inclusion in health research to enhance patient outcomes. This initiative supports CIRC's ongoing efforts to advance diagnostics and therapeutics for IBD patients in Canada.Global HomepageTakeda Canada Awards 1 Million To Support The Canadian IBD Research ConsortiumTakeda Canada awarded a $1 million PIONEER Grant to the Canadian Inflammatory Bowel Disease Research Consortium (CIRC) on February 3, 2022. The funding aims to support clinical research conducted by CIRC members to improve patient outcomes and advance diversity, equity, and inclusion in IBD studies. This grant facilitates ongoing multi-centre investigator-initiated studies designed to answer critical clinical questions regarding Crohn’s disease and ulcerative colitis.